2'-DeoxyinosineCAS# 890-38-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 890-38-0 | SDF | Download SDF |
| PubChem ID | 65058 | Appearance | White powder |
| Formula | C10H12N4O4 | M.Wt | 252.23 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one | ||
| SMILES | C1C(C(OC1N2C=NC3=C2NC=NC3=O)CO)O | ||
| Standard InChIKey | VGONTNSXDCQUGY-RRKCRQDMSA-N | ||
| Standard InChI | InChI=1S/C10H12N4O4/c15-2-6-5(16)1-7(18-6)14-4-13-8-9(14)11-3-12-10(8)17/h3-7,15-16H,1-2H2,(H,11,12,17)/t5-,6+,7+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
2'-Deoxyinosine Dilution Calculator
2'-Deoxyinosine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9646 mL | 19.8232 mL | 39.6464 mL | 79.2927 mL | 99.1159 mL |
| 5 mM | 0.7929 mL | 3.9646 mL | 7.9293 mL | 15.8585 mL | 19.8232 mL |
| 10 mM | 0.3965 mL | 1.9823 mL | 3.9646 mL | 7.9293 mL | 9.9116 mL |
| 50 mM | 0.0793 mL | 0.3965 mL | 0.7929 mL | 1.5859 mL | 1.9823 mL |
| 100 mM | 0.0396 mL | 0.1982 mL | 0.3965 mL | 0.7929 mL | 0.9912 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,4-Dihydroxyacetophenone
Catalog No.:BCN4441
CAS No.:89-84-9
- Thymol
Catalog No.:BCN3794
CAS No.:89-83-8
- Pulegone
Catalog No.:BCN3856
CAS No.:89-82-7
- (+)-Menthone
Catalog No.:BCC9239
CAS No.:89-80-5
- Neoisomenthol
Catalog No.:BCC8169
CAS No.:20752-34-5
- Mesalamine
Catalog No.:BCC4798
CAS No.:89-57-6
- Edaravone
Catalog No.:BCC2480
CAS No.:89-25-8
- Quinolinic acid
Catalog No.:BCC6573
CAS No.:89-00-9
- Dipsanoside B
Catalog No.:BCN2878
CAS No.:889678-64-2
- Dipsanoside A
Catalog No.:BCN2877
CAS No.:889678-62-0
- Mogrol
Catalog No.:BCN8446
CAS No.:88930-15-8
- Mogroside IVe
Catalog No.:BCN3166
CAS No.:88915-64-4
- LUF6000
Catalog No.:BCC1710
CAS No.:890087-21-5
- Nutlin-3
Catalog No.:BCC2254
CAS No.:890090-75-2
- WDR5 0103
Catalog No.:BCC5626
CAS No.:890190-22-4
- Dregeoside A11
Catalog No.:BCN3993
CAS No.:89020-11-1
- erythro-Guaiacylglycerol beta-coniferyl ether
Catalog No.:BCN1315
CAS No.:890317-92-7
- VU 29
Catalog No.:BCC7936
CAS No.:890764-36-0
- VU 1545
Catalog No.:BCC7649
CAS No.:890764-63-3
- ML 349
Catalog No.:BCC5612
CAS No.:890819-86-0
- GSK 650394
Catalog No.:BCC4070
CAS No.:890842-28-1
- 24,25-Epoxytirucall-7-en-3,23-dione
Catalog No.:BCN4437
CAS No.:890928-81-1
- BAMB-4
Catalog No.:BCC5428
CAS No.:891025-25-5
- 4-O-Demethylisokadsurenin D
Catalog No.:BCN6650
CAS No.:89104-59-6
The Bioactivity of D-/L-Isonucleoside- and 2'-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression.[Pubmed:29246300]
Mol Ther Nucleic Acids. 2017 Dec 15;9:218-229.
In this study, chemical modification of 2'-deoxyinosine (2'-dI) and D-/L-isothymidine (D-/L-isoT) was performed on AS1411. They could promote the nucleotide-protein interaction by changing the local conformation. Twenty modified sequences were obtained, FCL-I and FCL-II showed the most noticeable activity improvement. They stabilized the G-quadruplex, remained highly resistant to serum degradation and specificity for nucleolin, further inhibited tumor cell growth, exhibited a stronger ability to influence the different phases of the tumor cell cycle, induced S-phase arrest, promoted the inhibition of DNA replication, and suppressed the unwound function of a large T antigen as powerful as AS1411. The microarray analysis and TaqMan PCR results showed that FCL-II can upregulate the expression of four breast-cancer-related, lowly expressed miRNAs and downregulate the expression of three breast-cancer-related, highly expressed miRNAs (>2.5-fold). FCL-II resulted in enhanced treatment effects greater than AS1411 in animal experiments (p < 0.01). The computational results further proved that FCL-II exhibits more structural advantages than AS1411 for binding to the target protein nucleolin, indicating its great potential in antitumor therapy.
